Ascelia Pharma AB ( (SE:ACE) ) has issued an update.
Ascelia Pharma AB’s annual general meeting on May 7, 2025, resulted in several key resolutions, including the adoption of financial statements, re-election of board members, and authorization for the board to issue new shares to raise capital. The meeting also approved remuneration for board members and auditors, and authorized the transfer of shares to manage social security payments. However, a proposed long-term incentive program was withdrawn due to insufficient shareholder support.
More about Ascelia Pharma AB
Ascelia Pharma AB is a pharmaceutical company based in Malmö, Sweden, focusing on the development of novel drugs for oncology and rare diseases. The company aims to address unmet medical needs through innovative treatments, primarily targeting the global market.
Average Trading Volume: 780,459
Current Market Cap: SEK432.8M
For a thorough assessment of ACE stock, go to TipRanks’ Stock Analysis page.